RFA-HD-25-008: Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $300,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on March 29, 2024.
From the official notice on Grants.gov, last changed November 2, 2023. Checked November 7, 2026.
- Award ceiling$300,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR61 / R33
- Clinical trialsNot allowed
- Funded byNICHD
- Median yearly award$518,754
- Typical project length2.5 years
- R61, Exploratory/Developmental Phase I. The first phase of a phased award. Moving on to the R33 phase depends on meeting agreed milestones. Other open R61 notices.
- R33, Exploratory/Developmental Grant Phase II. The second phase of a phased award, usually following an R61 or R21 phase. Other open R33 notices.
Projects funded under RFA-HD-25-008 were run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-HD-25-008 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-HD-24-002 | October 13, 2022 | Closed March 29, 2023 | Closed |
Key dates
| Posted | November 2, 2023 |
|---|---|
| Deadline | March 29, 2024 |
| Archived by Grants.gov | May 4, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $518,754; it allows up to $300,000 per award.
- Most of the program's money (72% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this notice of funding opportunity announcement (NOFO) is to support and facilitate multidisciplinary research approaches for the development of novel nonsteroidal contraceptive products for men and women that act prior to fertilization. This NOFO aims to position innovative and validated methods for future clinical development.
Funded under RFA-HD-25-008 so far
NIH funded 6 projects under RFA-HD-25-008 in fiscal 2025 to 2026, at 4 institutions. The median yearly award was $518,754.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Multipurpose Device for Female-initiated Nonsteroidal On-Demand Contraception | St. Louis College of Pharmacy | 2026 | $695,773 |
| Development of a bioadhesive vaginal film for extended release of MPT antibodies | University of Pittsburgh at Pittsburgh | 2026 | $672,881 |
| Development of an ultrapotent anti-sperm antibody construct for non-hormonal contraception | Mucommune, LLC | 2026 | $550,000 |
| Development of an ultrapotent anti-sperm antibody construct for non-hormonal contraception | Mucommune, LLC | 2025 | $380,692 |
| Development of a bioadhesive vaginal film for extended release of MPT antibodies | Magee-Women's Res Inst and Foundation | 2025 | $518,754 |
| Multipurpose Device for Female-initiated Nonsteroidal On-Demand Contraception | St. Louis College of Pharmacy | 2025 | $474,946 |
Who has won Child Health and Human Development Extramural Research grants before
From fiscal 2021 to 2025, Child Health and Human Development Extramural Research (93.865) awarded $6.0 billion across 6,026 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 167 | $178 million |
| The Johns Hopkins University | Maryland | 133 | $146 million |
| University of Washington | Washington | 114 | $131 million |
| Baylor College of Medicine | Texas | 116 | $124 million |
| The Leland Stanford Junior University | California | 104 | $116 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-HD-25-008 still open?
No. It closed on March 29, 2024.
Who can apply for Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allowed)?
Closed March 29, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $300,000 each.
Who has been funded under RFA-HD-25-008?
NIH RePORTER lists 6 projects funded under RFA-HD-25-008 in fiscal 2025 to 2026, at 4 institutions. The most were at St. Louis College of Pharmacy, Mucommune, LLC, University of Pittsburgh at Pittsburgh.
Who has won Child Health and Human Development Extramural Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Johns Hopkins University, University of Washington. The program made 6,026 awards worth $6.0 billion in that time.
Similar open grants
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)